Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease: HELP
Articles by Joseph A. Murray
Based on 3 articles published since 2010
(Why 3 articles?)

Between 2010 and 2020, J. A. Murray wrote the following 3 articles about Crohn Disease.
+ Citations + Abstracts
1 Editorial Editorial: serologic microbial associated markers to predict Crohn's disease behaviour - authors' reply. 2016

Colombel, J-F / Riddle, M S / Murray, J A. ·Icahn School of Medicine at Mount Sinai, New York, NY, USA. jean-frederic.colombel@mssm.edu. · Naval Medical Research Center, Silver Spring, MD, USA. · Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. ·Aliment Pharmacol Ther · Pubmed #27375094.

ABSTRACT: -- No abstract --

2 Article Phenotype and Clinical Course of Inflammatory Bowel Disease With Co-existent Celiac Disease. 2018

Tse, Chung Sang / Deepak, Parakkal / De La Fuente, Jaime / Bledsoe, Adam C / Larson, Joseph J / Murray, Joseph A / Papadakis, Konstantinos A. ·Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. · Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. · Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. ·J Crohns Colitis · Pubmed #29741603.

ABSTRACT: Background and Aims: Inflammatory bowel diseases, principally Crohn's disease and ulcerative colitis, and celiac disease are among the most common immune-mediated gastrointestinal diseases. We aim to elucidate the clinical course and outcomes of patients with concomitant inflammatory bowel disease and celiac disease, a unique population that remains scarcely studied to date. Methods: A retrospective matched case-control study of adults with co-existent inflammatory bowel disease [IBD] and celiac disease was performed at a tertiary referral institution in North America. Logistic regression and Kaplan-Meier curves compared disease characteristics and clinical outcomes of the two groups. Results: A total of 342 inflammatory bowel disease patients were included in this study, of whom 114 had co-existent celiac disease and 228 did not. Patients with co-existent inflammatory bowel disease and celiac disease had higher rates of primary sclerosing cholangitis [19.3% vs 5.7%; odds ratio, 4.4; 95% confidence interval, 2.1-9.4; p <0.001], extensive ulcerative colitis [78.1% vs 59.0%; odds ratio, 2.8; 95% confidence interval, 1.5-5.5; p =0.002], and family history of celiac disease [10.5% vs 3.5%; odds ratio 3.2; 95% confidence interval, 1.3-8.2; p =0.01], compared with patients without concomitant celiac disease. Conclusions: Patients with inflammatory bowel disease with concomitant celiac disease have unique phenotypic features compared with non-celiac inflammatory bowel disease, with higher risks for colitis-related hospitalisations, extensive colitis, and primary sclerosing cholangitis. Increased recognition of co-existent IBD and celiac disease can prompt clinicians to investigate for concomitant disease sooner, particularly in patients with seemingly refractory disease.

3 Article Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. 2016

Choung, R S / Princen, F / Stockfisch, T P / Torres, J / Maue, A C / Porter, C K / Leon, F / De Vroey, B / Singh, S / Riddle, M S / Murray, J A / Colombel, J F / Anonymous8530865. ·Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. · Prometheus Laboratories Inc., San Diego, CA, USA. · Icahn School of Medicine at Mount Sinai, New York, NY, USA. · Naval Medical Research Center, Silver Spring, MD, USA. · Janssen R&D, Spring House, PA, USA. · Department of Gastroenterology, Hôpital de Jolimont, Haine-Saint-Paul, Belgium. · Gastroenterology Unit, Université Lille Nord de France, CHU Lille, Lille, France. ·Aliment Pharmacol Ther · Pubmed #27117843.

ABSTRACT: BACKGROUND: Patients with Crohn's disease (CD) have serologic responses to various microbial antigens. Serologic markers are associated with aggressive forms of disease and can be detected before onset of symptoms. Their utility in pre-clinical disease or prediction of complicated disease course before diagnosis is unclear. AIM: To evaluate the pattern of serologic anti-microbial antibodies long prior to diagnosis and the subsequent risk of complicated Crohn's disease at diagnosis. METHODS: Sera from 100 US military personnel with Crohn's disease were obtained from the Department of Defense Serum Repository. For each patient, four samples were obtained at different time points before and around diagnosis, and were tested for 6 microbiota-directed antibodies (ASCA-IgA, ASCA-IgG, anti-OmpC, anti-CBir1, anti-A4-Fla2 and anti-FlaX). Associations between the presence and accumulation of Crohn's disease anti-microbial antibodies before diagnosis and with the later development of complications were evaluated. RESULTS: Overall, 65 patients were positive for at least one Crohn's disease associated anti-microbial antibody in the earliest available sample, at a median of 6 years before Crohn's disease diagnosis (interquartile range, 5.6-8.2). The number of positive anti-microbial antibodies increased up to the time of Crohn's disease diagnosis. Complicated disease developed around the time of diagnosis in 24 patients. The proportion of positive antimicrobial antibodies before diagnosis was higher in patients with complicated vs. noncomplicated Crohn's disease. There was an inverse relationship between the time to first complication and the magnitude of serologic response before diagnosis. CONCLUSION: The presence and accumulation of circulating anti-microbial antibodies years before Crohn's disease diagnosis was associated with complicated Crohn's disease at or shortly after diagnosis.